Medication prescribing practice changed following the publications of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) in 2002 and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) in 2003. Few data are available on changes in hypertension control rates for patients initiating antihypertensive treatment before and after these publications. The authors compared systolic and diastolic blood pressure (SBP and DBP) levels and hypertension control (SBP <140 mm Hg and DBP <90 mm Hg) rates in patients initiating antihypertensive treatment in a large managed care organization during 2 time periods:
2002 (n=322); and July 1, 2003 , to June 30, 2004 . The blood pressure reduction associated with antihypertensive medication initiation was similar in 2001-2002 and 2003-2004 (−11.9 and −10.5 mm Hg, respectively, P=.251 for SBP; −6.9 and −5.9 mm Hg, respectively, P=. 160 for DBP). The mean SBP and DBP prior to treatment were significantly lower in 2003-2004 vs 2001-2002 (145.4 vs 151.3 mm Hg, P<.001 for SBP; 87.6 vs 90.1 mm Hg, P<.002 for DBP). Hypertension control rates increased from 38.0% to 50.2% (P=.005) from 2001-2002 to 2003-2004 . Lower pretreatment SBP and DBP explained hypertension control improvement over time.
In this real-world clinic population, antihypertensive treatment was initiated at lower blood pressure levels following publication of ALLHAT and JNC 7, resulting in substantial improvements in hypertension control rates.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) addressed the question of whether doxazosin, amlodipine, and lisinopril reduced coronary heart disease (CHD) and other outcomes more than chlorthalidone. The ALLHAT results, published in December 2002, found no difference in the incidence of fatal CHD and nonfatal myocardial infarction in the chlorthalidone group compared with the doxazosin, amlodipine, and lisinopril groups. 1 The incidence of stroke, heart failure, and combined cardiovascular disease outcomes were lower in the chlorthalidone group compared with the doxazosin and lisinopril groups, and the rate of heart failure was lower in the chlorthalidone group compared with the amlodipine group. 1, 2 Based on ALLHAT and results from other outcome trials in hypertension since the 1960s, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) in 2003 recommended that a thiazide-type diuretic be used alone or in combination with another agent as initial pharmacologic antihypertensive therapy in most patients, unless a compelling indication for use of an alternate medication was present. 3 Several studies have reported an increase in the inclusion of diuretics as part of the treatment regimen for patients initiating antihypertensive medication following publication of the major ALLHAT findings and JNC 7. [4] [5] [6] However, changes in blood pressure (BP) levels and hypertension control rates for patients initiating treatment during this period have not been well studied. There are several factors that could contribute to improvement in BP levels and hypertension control rates including more effective pharmacotherapy with use of thiazide-type diuretics, initiation of pharmacologic therapy with ≥2 classes of antihypertensive medications, and initiation of pharmacologic therapy at lower BP levels. The current analyses were conducted to contrast changes in BP and hypertension control in patients initiating antihypertensive treatment after vs before the publication of the major outcomes of ALLHAT in December 2002 and JNC 7 guidelines in May 2003. 1, 3 Additionally, we examined factors associated with hypertension control following initiation of antihypertensive medication.
Methods

Study Population
The patients identified for this study were drawn from a large managed care organization located in the southeastern United States that offered health care benefits to nearly 200,000 persons enrolled in commercial or Medicare plans. All patients initiating antihypertensive treatment during two time periods were identified. The first period was from July 1, 2001, to June 30, 2002, and represents patients initiating antihypertensive medication prior to the publication of ALLHAT and JNC 7. The second period was from July 1, 2003 , to June 30, 2004 , and represents patients initiating antihypertensive medication after these publications.
To identify patients initiating antihypertensive medication, we restricted the population to adults 21 years and older who remained continuously enrolled in the managed care organization for at least 3 years with no antihypertensive prescriptions filled in the 2 years prior to the study period (eg, from July 1, 1998 5 The current analyses targeted a stratified random population of 800 patients (ie, 400 from the first period: 2001-2002 and 400 from the second period: 2003-2004). For each period, an equal proportion of patients initiating treatment with thiazide-type diuretics vs without thiazide-type diuretics were selected. Of the 800 patients selected for chart abstraction, 645 met inclusion criteria, had charts available, and had BP measurements recorded before and after initiation of treatment. The populations selected for BP abstraction for each period were similar to the overall population initiating antihypertensive therapy, with the exception that those selected for chart abstraction during the 2001-2002 period were more likely to be taking ≥2 drug classes while those from 2003-2004 were less likely to be taking ≥2 drug classes.
Data Collection
The warehouse system for the managed care organization was the source of the administrative patient record data including age and sex. Race information was abstracted from patients' medical records. Pharmacy data included antihypertensive prescription fill dates and generic and brand names. Antihypertensive agents were grouped into 6 classes: diuretics (thiazide-type, loop, and potassium-sparing), β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and others (eg, α-/β-blocker, adrenolytic peripheral, and adrenolytic central). Data on select comorbid conditions were extracted from administrative databases using primary and secondary diagnosis and procedure codes (ie, diabetes mellitus [ICD-9 250.XX], myocar-dial infarction [ICD-9 codes 410.XX and 412.XX], heart failure [ICD-9 428. XX], and chronic kidney disease [ICD-9 580.XX -589.XX, 753.1, 593.XX, 403.XX, and 404.XX]).
BP readings (systolic BP [SBP] and diastolic BP [DBP]
) were abstracted from outpatient medical records. All BP measurements recorded for the clinic visits during the 3-month interval prior to each patient's initial antihypertensive medication fill and during the 6-month interval following the fill were abstracted onto standardized data collection forms by trained research personnel. Using all available values, SBP and DBP readings were averaged for each patient for the period prior to filling antihypertensive medication and separately for the period after filling antihypertensive medication.
All aspects of the study were approved by the institutional review boards of Tulane University, Ochsner Clinic Foundation, and the privacy committee of the managed care organization. All patient identification information was collected and maintained according to Health Insurance Portability and Accountability Act regulations and the managed care organization's privacy rules.
Statistical Methods
Characteristics of patients initiating antihypertensive medication were calculated for the 2001-2002 and 2003-2004 periods, overall and after additional stratification by inclusion of a thiazide-type diuretic as part of first-line therapy. Mean SBP and DBP levels prior to and subsequent to initiating antihypertensive medication were calculated for each period and compared across periods using 2-sample t tests. Change in BP from before to after the initiation of antihypertensive medication was calculated for each period and compared across periods using 2-sample t tests. Also, the difference in change for SBP and DBP associated with initiating antihypertensive medication across time periods was calculated in nested linear regression models with progressive adjustment. In addition to unadjusted and age-, race-, and sex-adjusted models, a final model included further adjustment for a thiazide-type diuretic, the number of antihypertensive medication classes being part of the initial treatment regimen, and history of diabetes, myocardial infarction, heart failure, and chronic kidney disease. Next, the percentage of patients with controlled hypertension (ie, SBP<140 mm Hg and DBP <90 mm Hg) was calculated prior to and subsequent to initiation of antihypertensive therapy. Using log-binomial regression models and restricting the analysis to patients with uncontrolled hypertension (ie, SBP ≥140 mm Hg or DBP ≥90 mm Hg) prior to initiating therapy, prevalence ratios for hypertension control subsequent to initiating antihypertensive therapy comparing patients in the 2003-2004 vs 2001-2002 period were calculated. Prevalence ratios are recommended instead of odds ratios for crosssectional studies with common outcomes. 7 Prevalence ratios included progressive adjustment as described above. Finally, prevalence ratios for hypertension control subsequent to initiating antihypertensive treatment associated with patient and treatmentrelated characteristics were calculated for the overall study population using a log-binomial regression model. Characteristics studied in an initial model included age, race, sex, diabetes, heart failure, chronic kidney disease, inclusion of a thiazide-type diuretic as part of initial therapy, number of antihypertensive drug classes, and time period. A subsequent model also included pretreatment SBP (140-149 mm Hg, 150-159 mm Hg, and ≥160 mm Hg) and DBP (90-99 mm Hg, 100-109 mm Hg, and ≥110 mm Hg). In a sensitivity analysis, we used SBP/DBP <130/80 mm Hg to define hypertension control for patients with a diagnosis of diabetes or chronic kidney disease. Change in SBP and DBP from before to after initiating antihypertensive treatment associated with patient characteristics were calculated for the overall study population using multivariable linear regression models. Analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC) and Stata version 9.0 (Stata Corporation, College Station, TX).
Results
Patient Characteristics
The age, race, and sex distributions of patients initiating antihypertensive medications were similar in the two time periods (Table I) . Additionally, with the exception of diabetes, which was more common in the 2003-2004 period, both in those with a regimen including a thiazide-type diuretic and those not including a thiazide-type diuretic, there were no differences in the prevalence of comorbid conditions across the two time periods. In the 2001-2002 period, 39.4% of patients initiated pharmacologic antihypertensive therapy with ≥2 drug classes compared with 25.7% in [2003] [2004] . A decline in initiating antihypertensive medications with ≥2 drug classes was present for patients whose regimen included a thiazide-type diuretic as well as their counterparts initiating treatment without a thiazidetype diuretic. Patients initiating antihypertensive therapy with ≥2 medication classes vs a single class had a higher mean SBP (151.0 mm Hg vs 147.1 mm Hg, respectively; P=.006) and a higher mean DBP (90.5 mm Hg vs 88.0 mm Hg, respectively, P=.004).
BP Levels and Rates of Hypertension Control
The mean SBP and DBP levels prior to initiating antihypertensive therapy were significantly lower in 2003-2004 compared with 2001-2002 (Table II) Table III ). The prevalence ratio for BP control comparing the 2003-2004 vs 2001-2002 time period was 1.32 (95% CI, 1.01-1.72) after multivariable adjustment for age, race, sex, thiazide-type diuretic use, number of medication classes, diabetes, myocardial infarction, congestive heart failure, and chronic kidney disease.
Factors Associated With Hypertension Control
In an initial multivariable model including age, race, sex, diabetes, congestive heart failure, chronic kidney disease, thiazide-type diuretic use, number of antihypertensive medication classes and time period (2003-2004 vs 2001-2002) , the only factor significantly associated with hypertension control was time period (Table IV) . Specifically, compared to their counterparts initiating treatment in 2001 to 2002, the prevalence ratio for achieving hypertension control was 1.32 (1.01-1.72) for those initiating antihypertensive treatment in [2003] [2004] . In a second model that also included adjustment for pretreatment SBP and DBP, time period was no longer significantly associated with hypertension control (prevalence ratio, 1.21; 95% CI, 0.93-1.58; P=.163). Compared with patients with a pretreatment systolic BP of 140 mm Hg to 149 mm Hg, the prevalence ratios for hypertension control associated with pretreatment SBP of 150 mm Hg to 159 mm Hg and ≥160 mm Hg were 0.62 (95% CI, 0.44-0.86) and 0.51 (95% CI, 0.36-0.72), respectively. Pretreatment DBP levels were not associated with hypertension control following initiation of treatment.
Factors Associated With Change in BP
After multivariable adjustment, a diagnosis of diabetes was associated with a smaller reduction in SBP, and filling ≥2 classes of antihypertensive medications was associated with a larger reduction in DBP from before to after initiation of antihypertensive treatment (Table  SI) . Other factors studied, including time period, were not associated with change in SBP or DBP (all P>.1).
Sensitivity Analyses
The percentage of patients with hypertension control increased from 31.0% to 39.6% (P=. 033) from 2001-2002 to 2003-2004 when SBP/DBP <130/80 mm Hg was used to define hypertension control for patients with a diagnosis of diabetes mellitus or chronic kidney disease. Consistent with the main analyses, pretreatment SBP levels, but not pretreatment DBP levels, were associated with hypertension control in sensitivity analyses (data not shown). Previous studies have evaluated changes in antihypertensive prescription patterns from before to after publication of the main ALLHAT findings and the JNC 7 guidelines. 4, 5, [8] [9] [10] In our prior work, the percentage of patients initiating antihypertensive treatment with a thiazide-type diuretic increased from 30.6% to 39.4% (P<.001) between 2001-2002 and 2003-2004. During the same period, the percentage of patients initiating treatment with calcium channel blockers decreased from 16.7% to 13.8% (P<.05) while the percentage of patients initiating treatment with renin angiotensin system blockers did not change (41.4% to 43.7%; P>.05). 5 Despite different study populations and methodologies, a similar increase in the use of thiazide-type diuretics was reported in several other populations. 4, 5, 8, 10 Collectively, these studies suggest that large randomized controlled trials and clinical practice guidelines may change provider prescribing patterns. outcomes in real-world settings, 11 few data are available on the effect of the change in prescribing practices on BP and hypertension control in actual clinical practice. Use of thiazide-type diuretics, initiation of pharmacologic therapy with ≥2 antihypertensive medication classes, initiation of pharmacologic therapy at lower BP levels, and increases in lifestyle changes such as exercise and decreasing dietary salt intake are all factors that could contribute to improvements in BP levels and hypertension control rates. In this study, we sampled equal numbers of patients using thiazide-type diuretics in the 2001-2002 and 2003-2004 periods and thus controlled for use of thiazide-type diuretics. We did not identify an effect of initiating ≥2 antihypertensive medication classes on hypertension control rates. This may be due to patients initiating therapy with ≥2 classes of medications having higher SBP and DBP prior to initiating therapy and having more difficulty in controlling hypertension. Initiation of pharmacologic therapy at lower BP levels was observed and associated with a higher likelihood for hypertension control. Although lifestyle changes could contribute to improved BP control, we were unable to accurately capture the use of lifestyle changes with our retrospective study design using administrative databases.
Discussion
In the current study, improved BP control was present in the period following ALLHAT and JNC 7. The improvement in hypertension control following ALLHAT and JNC 7 observed in this analysis is likely related to the lower SBP levels at treatment initiation in the 2003-2004 period and may be the result of increased awareness about the treatment and control of hypertension. Data from the National Health and Nutrition Examination Study (NHANES) revealed that the proportion of US adults achieving hypertension control increased from 27.3% in 1988-1994 to 50.1% in 2007-2008. 12 These data indicate that the Healthy People 2010 goal for hypertension control is being met and reflects increases in awareness, treatment, and percentage of patients with hypertension treated and controlled. The current study extends prior research on hypertension control among patients with prevalent hypertension to a population of patients initiating therapy. Additionally, a potential reason for the improvement in hypertension control rates (ie, initiating therapy at lower BP levels) was identified.
Limitations and Strengths
The results of our analyses need to be interpreted within the context of its limitations. Most importantly, it focused on a patient population with health insurance in a large managed care organization from one region of the United States. The study population was restricted to patients with BP recorded before and after initiation of antihypertensive therapy and differed from the source population with respect to number of antihypertensive medications prescribed as part of their initial therapy; however, we do not believe that this affects the overall study inferences with respect to the time trends in hypertension control. The BPs recorded were abstracted from medical records and were not measured as part of a study protocol. Doses for medications filled were not readily available. Chlorthalidone was used by few patients in this study, and better hypertension control rates could be achieved with increased chlorthalidone use. 13 Hypertension and comorbid conditions were identified using administrative data (eg, ICD-9 codes). We did not verify that JNC 7 criteria for a hypertension diagnosis were met, which is a limitation of using real-world data. Given the modest sample size for the current study, we may have lacked statistical power to detect factors associated with BP control. For example, similar to other studies, black patients were less likely than white patients to have controlled hypertension following treatment initiation, 14, 15 but this difference was not significant in the current study. To our knowledge, no targeted treatment or incentive programs on the part of the managed care organization were initiated during the study timeframe. Given that the results of ALLHAT were primary drivers for the development of JNC 7, they were published over a short timeline and general education programs were also implemented around the same time, we were not able to tease out impact of ALLHAT vs JNC 7 vs secular trends. It is possible that the improved BP control observed resulted from increased awareness about hypertension given widespread general promotional efforts about hypertension during the period studied.
The study also exhibits several strengths. The data from the administrative databases provided clinically relevant information such as comorbid diagnoses. We were able to limit the population to patients who had not filled an antihypertensive medication in the 2 years prior to the study period. Also, the use of administrative databases permitted us to analyze patients with an outpatient primary diagnosis of hypertension. These criteria provide confidence that the patients studied were initiating a pharmacologic regimen for the treatment of hypertension.
Conclusions
In a real-world setting, we observed improvements in hypertension control from before to after the publications of ALLHAT and JNC 7. These data extend recent estimates from NHANES 12 to demonstrate time trends in improved hypertension control among patients initiating therapy. The improvement in hypertension control was primarily due to patients initiating therapy at lower BP levels in the more contemporary time period. These results reveal that changes in prescribing practices were associated with clinically meaningful improvements in BP and hypertension control in actual clinical practice.
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